Dr. Michael Burgess graduated from David Geffen School of Medicine at UCLA in 2007. He did his residency in internal medicine at the University of California, San Francisco. He also completed a fellowship in hematology and medical oncology in 2012 at the University of California, San Francisco. He is a board-certified medical oncologist and currently practices at the UCSF Medical Center. During his vast clinical experience, he contributed to several research publications.
David Geffen School of Medicine at UCLA
American Board of Internal Medicine - Oncology
Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis.
Wong, J. C.,Weinfurtner, K. M.,Alzamora, M. D.,Kogan, S. C.,Burgess, M. R.,Zhang, Y.,Nakitandwe, J.,Ma, J.,Cheng, J.,Chen, S. C.,Ho, T. T.,Flach, J.,Reynaud, D.,Passeg...; Elife. 2015 Jul 21.See more >>
Preclinical efficacy of MEK inhibition in Nras-mutant AML.
Burgess MR Hwang E Firestone AJ Huang T Xu J Zuber J Bohin N Wen T Kogan SC Haigis KM Sampath D Lowe S Shannon K Li Q; Blood. 2014 Dec 18 .See more >>
MAGI-2 scaffold protein is critical for kidney barrier function.
Balbas MD Burgess MR Murali R Wongvipat J Skaggs BJ Mundel P Weins A Sawyers CL; Proc Natl Acad Sci U S A. 2014 Sep 30 .See more >>